Thirunavukkarasu Angappan: What mRNA Manufacturing Teaches Us About Scaling Hemophilia Gene Therapy
Thirunavukkarasu Angappan, Vice President of Operations and Manufacturing at PopVax, shared a post on LinkedIn:
”What mRNA Manufacturing Teaches Us About Scaling Hemophilia Gene Therapy
Hemgenix costs 3.5 million dollar per dose.
Roctavian, 2.9 million dollar. One treatment, one lifetime, one very fragile factory.
- Vector manufacturing alone can cost 3–7 million dollar per 500L batch — and a single batch may only treat 2–3 adult hemophilia B patients.
- The industry still lacks a standardized, commercial-scale AAV/LNP manufacturing platform equivalent to what exists for monoclonal antibodies.
- The choice of upstream platform — transient HEK293 transfection vs. stable producer cell lines — remains the single most consequential, unresolved manufacturing decision in the field.
This is almost exactly the standardisation gap mRNA/LNP manufacturing faced in 2021 — proven at lab scale, unproven at commercial scale, every developer solving the same problems independently.
Having lived through that phase with mRNA, I’d bet gene therapy manufacturers are about to relearn several of the same lessons the hard way.
Will AAV gene therapy manufacturing repeat mRNA’s early growing pains — or has the industry actually absorbed that lesson this time?”

Stay updated with Hemostasis Today.
-
Nov 8, 2026, 12:22Marc Carrier: Advancing Catheter-Related Thrombosis Prevention Through Factor XI Inhibition
-
Nov 8, 2026, 11:56Why Genetic Predisposition Does Not Always Lead to Thrombosis – Stork Genetics
-
Nov 8, 2026, 11:45Sher-Lu Pai: Investigating Intracardiac Thrombosis and Its Management in Liver Transplantation
-
Nov 8, 2026, 11:25Mehmet Cilingiroglu: Navigating Anticoagulation Choices in Acute Coronary Syndrome PCI
-
Nov 8, 2026, 07:16Gilberto de lima Lopes Junior: The Cardiovascular Consequences of Cancer in Younger Patients
-
Nov 8, 2026, 06:51Haney Mallemat: Key Principles and Pitfalls of LVAD Emergencies
-
Nov 8, 2026, 06:31Maria Omer: Clinical Recognition and Management of Cavernous Sinus Thrombosis
-
Nov 8, 2026, 06:16Natasha Jolakoski: University of New Mexico Hospital Promotes PGY-2 Thrombosis and Hemostasis Management Pharmacy Residency
-
Nov 8, 2026, 05:47Safaa Hilal: POCUS in the Evaluation of Perioperative Troponin Elevation